FI3439668T3 - Pienimolekyylivälitteinen hengitysteiden pinnan fysiologian palauttaminen kystistä fibroosia sairastavan ihmisen keuhkojen epiteelissä - Google Patents
Pienimolekyylivälitteinen hengitysteiden pinnan fysiologian palauttaminen kystistä fibroosia sairastavan ihmisen keuhkojen epiteelissä Download PDFInfo
- Publication number
- FI3439668T3 FI3439668T3 FIEP17779973.1T FI17779973T FI3439668T3 FI 3439668 T3 FI3439668 T3 FI 3439668T3 FI 17779973 T FI17779973 T FI 17779973T FI 3439668 T3 FI3439668 T3 FI 3439668T3
- Authority
- FI
- Finland
- Prior art keywords
- cystic fibrosis
- composition
- small molecule
- airway surface
- amb
- Prior art date
Links
- 206010011763 Cystic fibrosis lung Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000035479 physiological effects, processes and functions Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 11
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 8
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 8
- 229960003942 amphotericin b Drugs 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 102220008557 rs121908746 Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320111P | 2016-04-08 | 2016-04-08 | |
| US201662320795P | 2016-04-11 | 2016-04-11 | |
| PCT/US2017/026806 WO2017177228A1 (en) | 2016-04-08 | 2017-04-10 | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3439668T3 true FI3439668T3 (fi) | 2024-09-05 |
Family
ID=60001496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17779973.1T FI3439668T3 (fi) | 2016-04-08 | 2017-04-10 | Pienimolekyylivälitteinen hengitysteiden pinnan fysiologian palauttaminen kystistä fibroosia sairastavan ihmisen keuhkojen epiteelissä |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190083517A1 (https=) |
| EP (1) | EP3439668B1 (https=) |
| JP (1) | JP7041961B2 (https=) |
| AU (1) | AU2017248394B2 (https=) |
| DK (1) | DK3439668T3 (https=) |
| ES (1) | ES2983639T3 (https=) |
| FI (1) | FI3439668T3 (https=) |
| PT (1) | PT3439668T (https=) |
| WO (1) | WO2017177228A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3439668B1 (en) | 2016-04-08 | 2024-06-19 | The Board of Trustees of the University of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
| FI3694526T3 (fi) | 2017-10-11 | 2025-02-06 | Univ Illinois | Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| CA2194049A1 (en) | 1994-06-28 | 1996-01-11 | Georgi Stankov | Novel clinical uses of polyene macrolides |
| TWI249408B (en) * | 2003-12-10 | 2006-02-21 | Ind Tech Res Inst | New antifungal formulation and manufacturing method thereof |
| AU2005251745A1 (en) * | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| WO2009006311A2 (en) * | 2007-06-29 | 2009-01-08 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| EP2488160B1 (en) * | 2009-10-16 | 2020-07-01 | Lifecare Innovations Pvt. Ltd. | Liposomal amphotericin formulation comprising cholesterol for treating fungal infections |
| KR102548341B1 (ko) * | 2013-10-07 | 2023-06-26 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 개선된 치료 지수를 갖는 암포테리신 b 유도체 |
| JP6796581B2 (ja) * | 2014-11-04 | 2020-12-09 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | ミッシングタンパク質の小分子模倣体を用いた生理機能の回復 |
| EP3439668B1 (en) | 2016-04-08 | 2024-06-19 | The Board of Trustees of the University of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
-
2017
- 2017-04-10 EP EP17779973.1A patent/EP3439668B1/en active Active
- 2017-04-10 US US16/091,599 patent/US20190083517A1/en not_active Abandoned
- 2017-04-10 ES ES17779973T patent/ES2983639T3/es active Active
- 2017-04-10 FI FIEP17779973.1T patent/FI3439668T3/fi active
- 2017-04-10 PT PT177799731T patent/PT3439668T/pt unknown
- 2017-04-10 DK DK17779973.1T patent/DK3439668T3/da active
- 2017-04-10 JP JP2018552659A patent/JP7041961B2/ja active Active
- 2017-04-10 AU AU2017248394A patent/AU2017248394B2/en active Active
- 2017-04-10 WO PCT/US2017/026806 patent/WO2017177228A1/en not_active Ceased
-
2021
- 2021-06-01 US US17/335,803 patent/US11850256B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3439668T3 (da) | 2024-09-02 |
| US20210393661A1 (en) | 2021-12-23 |
| EP3439668A1 (en) | 2019-02-13 |
| AU2017248394A1 (en) | 2018-11-22 |
| EP3439668B1 (en) | 2024-06-19 |
| JP7041961B2 (ja) | 2022-03-25 |
| PT3439668T (pt) | 2024-08-12 |
| JP2019510788A (ja) | 2019-04-18 |
| US20190083517A1 (en) | 2019-03-21 |
| US11850256B2 (en) | 2023-12-26 |
| EP3439668A4 (en) | 2019-12-18 |
| WO2017177228A1 (en) | 2017-10-12 |
| AU2017248394B2 (en) | 2023-02-23 |
| ES2983639T3 (es) | 2024-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500765A1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| PH12018500088A1 (en) | Substituted tricyclics and method of use | |
| MY194313A (en) | Substituted chromanes and method of use | |
| HK1211475A1 (en) | Combination therapy | |
| TN2010000288A1 (en) | 4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof | |
| WO2016170348A8 (en) | Sarna compositions and methods of use | |
| MX2018004364A (es) | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| JP2013507408A5 (https=) | ||
| UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| PH12017502249A1 (en) | Tofacitinib orally disintegrating tablets | |
| FI3439668T3 (fi) | Pienimolekyylivälitteinen hengitysteiden pinnan fysiologian palauttaminen kystistä fibroosia sairastavan ihmisen keuhkojen epiteelissä | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| FI3694526T3 (fi) | Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten | |
| CN103748074B8 (zh) | 芳氧基喹啉类衍生物及其治疗用途 | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| WO2008131859A3 (de) | Verwendimg cyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie | |
| JP2018513862A5 (https=) | ||
| GB2588904B (en) | Improvements in, or relating to, the treatment of by-products | |
| ME02839B (me) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt | |
| CN104870437A (zh) | 三嗪化合物、其药用盐、异构体或水合物及其药物组合物 | |
| WO2008096081A3 (fr) | Utilisation du riluzole et de ses dérivés pour fabriquer de nouveaux médicaments | |
| HK40067294A (en) | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease | |
| WO2016004960A3 (en) | Misoprostol dispersible tablet |